Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $180.4552W HIGH $259.84
Volume
1.94 M
Value Traded
544.64 M
Short % Float
3.32%
Days to Cover
5.0
+0.36%Week
+12.58%1 Month
+8.89%3 Month
+28.29%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
58.00 B
EPS (TTM)
7.40
P/E Ratio
33.84
Ent. Value
53.14 B
Total Shares
231.56 M
Float Shares
231.00 M
Insiders
0.24%
Institutions
92.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CAH Catalyst Timeline
Dated clinical, regulatory and corporate events for Cardinal Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cardinal Health, Inc.
9Total events
3Upcoming
1Tier-1 (high impact)
2025 to 2032Coverage
Upcoming catalysts 2
Event history 5
▲Partnership / LicenseCorporate
Cardinal Health enters binding Letter of Intent to extend CVS Health pharmaceutical distribution agreements
●Runway Guidance UpdateCorporate
Cardinal Health reaffirms FY2027 non-GAAP EPS guidance of 13%-15% growth ($12.40-$12.60)
▼Legal / SettlementCorporate
Cardinal Health pays $17,500 attorneys' fees; sanctions motion withdrawn in New York case
▼Legal / SettlementCorporate
Texas federal court dismisses Cardinal Health breach of contract claims over Prefund Program
▼Legal / SettlementCorporate
Ohio federal court dismisses Cardinal Health lawsuit against customers
Past FDA Catalysts and PDUFA Decisions
How CAH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-05-19 | Lymphoseek Kit (technetium tc-99m tilmanocept) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 87%
Large Pharma(rank 572 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every CAH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hollar Jason M.Officer (Chief Executive Officer) | Sell | -6,206 228,926 held | $233.22 | 08/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CAH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 2.8 % (3.7 %) | 71.27 M | 300.00 K | 11.11% ( 30.00 K) |
CAH Institutional Ownership Trends
CAH Short Interest
Shares sold short, counted twice a month.
3.32%
Short % of Float
of tradable shares sold short
7.7M
Shares Sold Short
+4.2% vs prior count
5.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CAH ranks across every disease it competes in
Competitive Position is a premium feature
See how CAH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCAH News
-CAH
Oct 1, 2026Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
Cardinal Health has signed a binding Letter of Intent to extend its distribution agreement with CVS Health until June 30, 2032. This extension demonstrates the strength of their partnership and Cardinal Health's commitment to providing quality distribution services. The company also reaffirmed its EPS growth guidance for fiscal year 2027, indicating a positive outlook.
Read more →-CAH
Oct 1, 2026Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
Cardinal Health plans to announce its first-quarter financial results for fiscal year 2027 on November 5, before the market opens. The company will host a webcast at 8:30 a.m. Eastern to discuss these results. Investors can access the webcast and presentation slides on the Investor Relations page, which will be available for 12 months.
Read more →-CAH
Sep 19, 2026Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Cardinal Health 414, LLC, for Alleged Failure to Reimburse Employees' Business Expenses
A class action lawsuit has been filed against Cardinal Health 414, LLC by employment law attorneys alleging multiple violations of the California Labor Code. The lawsuit claims the company failed to reimburse employees for business expenses, did not pay minimum and overtime wages, and did not provide legally required meal and rest breaks. The case is currently pending in the San Diego County Superior Court.
Read more →-CAH
Sep 16, 2026Cardinal Health Loses Multiple "Product Return" Lawsuits Against Pharmacy Customers and Pays Attorneys' Fees to Settle Sanctions Motion for Frivolous Litigation
Cardinal Health has faced multiple legal setbacks, with three lawsuits against pharmacies dismissed due to vague contractual terms. A federal judge ruled that Cardinal could not prove its claims regarding 'ineligible' product returns. Additionally, Cardinal paid $17,500 to settle a sanctions motion for frivolous litigation. This follows previous dismissals in Ohio and highlights ongoing scrutiny of Cardinal's practices.
Read more →-CAH
Aug 11, 2026Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance
Cardinal Health reported strong financial results for the fourth quarter and fiscal year 2026, with revenues increasing by 6% to $63.7 billion and GAAP diluted EPS rising by 70% to $1.70. The company also announced a positive outlook for fiscal year 2027, projecting a non-GAAP EPS growth of 13-15%. Additionally, a significant share repurchase program was completed, reflecting confidence in future performance.
Read more →-CAH
Aug 11, 2026Cardinal Health Board of Directors Approves Quarterly Dividend
Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5158 per share, payable on October 15, 2026. Shareholders of record as of October 1, 2026, will receive this dividend, which is sourced from the company's capital surplus. This decision underscores the company's financial health and commitment to its investors.
Read more →-CAH
Jul 20, 2026Cardinal Health expands home care business with two tuck-in acquisitions
Cardinal Health has announced two acquisitions aimed at expanding its at-Home Solutions business, acquiring the Diabetes Health segment of AdaptHealth and Strive Medical for approximately $360 million. These acquisitions are expected to enhance Cardinal Health's capabilities in diabetes management and urology, building on previous investments in home care. The transactions are pending regulatory approvals and are projected to positively impact earnings in the first year post-acquisition.
Read more →-CAH
Jul 9, 2026Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
Cardinal Health plans to announce its fourth-quarter and year-end financial results for fiscal year 2026 on August 11, prior to the NYSE opening. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the company's Investor Relations page. Presentation materials will be available for a year.
Read more →-CAH
Apr 30, 2026Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook
Cardinal Health reported a strong third quarter for fiscal 2026 with revenues up 11% to $60.9 billion while non-GAAP operating earnings increased by 18%. However, GAAP operating earnings saw a 30% decline due to a goodwill impairment. The company has raised its non-GAAP EPS guidance for the year, reflecting improved performance in its Pharmaceutical and Specialty Solutions segment. Additionally, Cardinal Health has been active in share repurchases and debt reduction, enhancing its financial stability.
Read more →-CAH
Apr 14, 2026Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
Cardinal Health's 2026 Advanced Therapies Report reveals a shift towards administering advanced therapies in community settings. The report highlights strong provider support for these initiatives, emphasizing the importance of partnerships between health systems and community practices. It also notes the operational complexities and planning required to successfully implement these programs, which aim to enhance patient access and experience.
Read more →-CAH
Mar 24, 2026Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30
Cardinal Health plans to release its third-quarter financial results for fiscal year 2026 on April 30. The announcement includes a webcast discussion starting at 8:30 a.m. Eastern. Investors can access the webcast and presentation slides on the company's Investor Relations page.
Read more →-CAH
Feb 5, 2026▲ +9.8%on this news
Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook
Cardinal Health reported a significant revenue increase of 19% for Q2 FY2026, reaching $65.6 billion, alongside a 29% rise in GAAP operating earnings. The company has raised its fiscal year 2026 non-GAAP EPS guidance to $10.15 to $10.35, reflecting strong segment profit growth. Key contributions were noted in their Pharmaceutical and Specialty Solutions segment, despite challenges such as increased financing costs and adverse tariffs. Overall, the performance exemplifies solid growth across multiple segments and strategic initiatives.
Read more →-CAH
Jan 6, 2026Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5
Cardinal Health (NYSE: CAH) will announce its second-quarter financial results for fiscal year 2026 on February 5, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the Investor Relations page. The company emphasizes its commitment to customer-centric solutions and continuous improvement.
Read more →-CAH
Oct 30, 2025▲ +15.4%on this news
Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook
Cardinal Health reported strong financial results for the first quarter of fiscal year 2026, showing a 22% increase in revenue to $64 billion and an 18% rise in GAAP operating earnings. The company also raised its fiscal year 2026 EPS guidance, reflecting confidence in continued growth driven by successful operational performance across all segments. Cardinal Health is set to complete the acquisition of Solaris Health in early November, which may further influence its financial trajectory. Overall, the company demonstrates robust growth prospects despite some concerns about increased financing costs.
Read more →-CAH
Sep 23, 2025Cardinal Health to Announce First-Quarter Results for Fiscal Year 2026 on October 30
Cardinal Health plans to release its first-quarter financial results for fiscal year 2026 on October 30, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, allowing investors to access the information easily. The company highlights its commitment to customer-centric solutions in the healthcare sector.
Read more →-CAH
Aug 12, 2025▼ -7.2%on this news
Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance
Cardinal Health reported its fourth quarter and full year financial results for fiscal year 2025, revealing a flat revenue of $60.2 billion. Despite a decrease in overall revenue for the fiscal year, adjusted non-GAAP operating earnings rose, reflecting strong performance in its Pharmaceutical and Specialty Solutions segments. Additionally, the company announced an increase in non-GAAP EPS guidance for fiscal year 2026 to between $9.30 and $9.50. The company also confirmed its acquisition of Solaris Health, enhancing its multi-specialty service offerings.
Read more →-CAH
Jul 15, 2025Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2025 on August 12
Cardinal Health plans to release its fourth-quarter and year-end financial results for fiscal year 2025 on August 12, before the market opens. A webcast discussion will follow at 8:30 a.m. Eastern, accessible via the Investor Relations page. Presentation materials will be available for a year.
Read more →-CAH
Jun 12, 2025Cardinal Health Details Momentum and Updated Long-Term Value Creation Plans at Investor Day
Cardinal Health hosted an Investor Day where it announced updates to its financial guidance, including an increase in FY25 non-GAAP diluted EPS guidance and preliminary guidance for FY26. The company confirmed long-term growth targets and outlined strategic priorities in various sectors, including Pharmaceutical and Specialty Solutions. Cardinal Health expects significant cash flow generation and plans for substantial share repurchases.
Read more →-CAH
May 1, 2025Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
Cardinal Health announced its third quarter fiscal year 2025 results, reporting flat revenue at $54.9 billion while increasing its non-GAAP EPS guidance for the year to $8.05 to $8.15. The company witnessed a 21% increase in non-GAAP operating earnings, attributed to segment profit growth across all operating areas. Additionally, GI Alliance expanded into the urology therapeutic area and completed its acquisition of Advanced Diabetes Supply Group. Despite challenges, the company remains optimistic about future growth and innovation.
Read more →About Cardinal Health, Inc.
Headquarters7000 CARDINAL PLACE, DUBLIN, OH, 43017
BIOPHARMAWATCH ELITE PLUS
Trade the next CAH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime